VU0467485/AZ13713945的发现：一种被评估为治疗精神分裂症临床前候选药物的代谢型谷氨酸受体正向变构调节剂
Discovery of VU0467485/AZ13713945: An M PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia.
作者信息
Wood Michael R, Noetzel Meredith J, Melancon Bruce J, Poslusney Michael S, Nance Kellie D, Hurtado Miguel A, Luscombe Vincent B, Weiner Rebecca L, Rodriguez Alice L, Lamsal Atin, Chang Sichen, Bubser Michael, Blobaum Anna L, Engers Darren W, Niswender Colleen M, Jones Carrie K, Brandon Nicholas J, Wood Michael W, Duggan Mark E, Conn P Jeffrey, Bridges Thomas M, Lindsley Craig W
机构信息
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine , Nashville, Tennessee 37232, United States.
出版信息
ACS Med Chem Lett. 2016 Dec 16;8(2):233-238. doi: 10.1021/acsmedchemlett.6b00461. eCollection 2017 Feb 9.
Abstract
Herein, we report the structure-activity relationships within a series of potent, selective, and orally bioavailable muscarinic acetylcholine receptor 4 (M) positive allosteric modulators (PAMs). Compound (VU0467485) possesses robust M PAM potency across species and efficacy in preclinical models of schizophrenia. Coupled with an attractive DMPK profile and suitable predicted human PK, (VU0467485) was evaluated as a preclinical development candidate.
摘要
在此，我们报告了一系列强效、选择性且口服生物可利用的毒蕈碱型乙酰胆碱受体4（M4）正向变构调节剂（PAMs）的构效关系。化合物（VU0467485）在各物种中均具有强大的M4 PAM活性，且在精神分裂症临床前模型中有效。结合吸引人的药物代谢动力学（DMPK）特征和合适的预测人体药代动力学（PK），（VU0467485）被评估为临床前开发候选药物。
相似文献
1
Discovery of VU0467485/AZ13713945: An M PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia.
ACS Med Chem Lett. 2016 Dec 16;8(2):233-238. doi: 10.1021/acsmedchemlett.6b00461. eCollection 2017 Feb 9.
2
Synthesis and Preliminary Evaluation of C-Labeled VU0467485/AZ13713945 and Its Analogues for Imaging Muscarinic Acetylcholine Receptor Subtype 4.
ChemMedChem. 2019 Feb 5;14(3):303-309. doi: 10.1002/cmdc.201800710. Epub 2018 Dec 27.
3
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM).
ACS Chem Neurosci. 2024 Sep 24;15(20):3744-54. doi: 10.1021/acschemneuro.4c00465.
4
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.
ACS Med Chem Lett. 2015 May 20;6(6):716-20. doi: 10.1021/acsmedchemlett.5b00181. eCollection 2015 Jun 11.
5
Optimization of M positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.
Bioorg Med Chem Lett. 2017 Jun 1;27(11):2296-2301. doi: 10.1016/j.bmcl.2017.04.043. Epub 2017 Apr 13.
6
Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides.
Bioorg Med Chem Lett. 2017 Jul 1;27(13):2990-2995. doi: 10.1016/j.bmcl.2017.05.014. Epub 2017 May 6.
7
Discovery, Optimization, and Biological Characterization of 2,3,6-Trisubstituted Pyridine-Containing M Positive Allosteric Modulators.
ChemMedChem. 2019 May 6;14(9):943-951. doi: 10.1002/cmdc.201900088. Epub 2019 Mar 28.
8
Challenges in the development of an M PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.
Bioorg Med Chem Lett. 2017 Jan 15;27(2):171-175. doi: 10.1016/j.bmcl.2016.11.086. Epub 2016 Nov 30.
10
Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M PAM VU0467154.
Neuropharmacology. 2018 Jan;128:492-502. doi: 10.1016/j.neuropharm.2017.07.013. Epub 2017 Jul 17.
引用本文的文献
1
Discovery of Pre-Clinical Candidate /: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy.
ACS Chem Neurosci. 2025 Jun 4;16(11):2141-2162. doi: 10.1021/acschemneuro.5c00277. Epub 2025 May 26.
2
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM).
ACS Chem Neurosci. 2024 Sep 24;15(20):3744-54. doi: 10.1021/acschemneuro.4c00465.
3
A golden age of muscarinic acetylcholine receptor modulation in neurological diseases.
Nat Rev Drug Discov. 2024 Oct;23(10):743-758. doi: 10.1038/s41573-024-01007-1. Epub 2024 Aug 14.
4
Discovery of VU6008677: A Structurally Distinct Tricyclic M Positive Allosteric Modulator with Improved CYP450 Profile.
ACS Med Chem Lett. 2024 Jul 3;15(8):1358-1366. doi: 10.1021/acsmedchemlett.4c00249. eCollection 2024 Aug 8.
5
Imaging Cholinergic Receptors in the Brain by Positron Emission Tomography.
J Med Chem. 2023 Aug 24;66(16):10889-10916. doi: 10.1021/acs.jmedchem.3c00573. Epub 2023 Aug 15.
6
Characterization of a Novel M4 PAM PET Radioligand [11C]PF06885190 in Nonhuman Primates (NHP).
Molecules. 2023 Jun 7;28(12):4612. doi: 10.3390/molecules28124612.
7
The pyridazine heterocycle in molecular recognition and drug discovery.
Med Chem Res. 2023 Mar 15:1-69. doi: 10.1007/s00044-023-03035-9.
8
Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics.
Elife. 2023 May 30;12:e83477. doi: 10.7554/eLife.83477.
9
Structure-activity relationship of pyrazol-4-yl-pyridine derivatives and identification of a radiofluorinated probe for imaging the muscarinic acetylcholine receptor M.
Acta Pharm Sin B. 2023 Jan;13(1):213-226. doi: 10.1016/j.apsb.2022.07.008. Epub 2022 Jul 21.
10
Effects of acute and repeated administration of the selective M PAM VU0152099 on cocaine versus food choice in male rats.
Addict Biol. 2022 Mar;27(2):e13145. doi: 10.1111/adb.13145.
本文引用的文献
1
Challenges in the development of an M PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.
Bioorg Med Chem Lett. 2017 Jan 15;27(2):171-175. doi: 10.1016/j.bmcl.2016.11.086. Epub 2016 Nov 30.
2
Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release.
Neuron. 2016 Sep 21;91(6):1244-1252. doi: 10.1016/j.neuron.2016.08.017. Epub 2016 Sep 8.
3
Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M PAM VU6004256.
ACS Chem Neurosci. 2016 Dec 21;7(12):1706-1716. doi: 10.1021/acschemneuro.6b00230. Epub 2016 Oct 5.
4
Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.
Bioorg Med Chem Lett. 2016 Jul 1;26(13):3029-3033. doi: 10.1016/j.bmcl.2016.05.010. Epub 2016 May 5.
5
Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.
Chem Rev. 2016 Jun 8;116(11):6707-41. doi: 10.1021/acs.chemrev.5b00656. Epub 2016 Feb 16.
6
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.
ACS Med Chem Lett. 2015 May 20;6(6):716-20. doi: 10.1021/acsmedchemlett.5b00181. eCollection 2015 Jun 11.
7
Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model.
Neuropsychopharmacology. 2016 Jan;41(2):598-610. doi: 10.1038/npp.2015.189. Epub 2015 Jun 25.
8
Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.
Nat Rev Drug Discov. 2014 Sep;13(9):692-708. doi: 10.1038/nrd4308.
9
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.
ACS Chem Neurosci. 2014 Oct 15;5(10):920-42. doi: 10.1021/cn500128b. Epub 2014 Aug 19.
10
Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.
Neuropsychopharmacology. 2014 Jun;39(7):1578-93. doi: 10.1038/npp.2014.2. Epub 2014 Jan 20.
Zotero 插件